Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810383 | 0.83 | CA2 (0.50) | CA2CA1TP53MAPK1SLC1A3 | |
| SCHEMBL27697229 | 0.83 | CA2 (0.50) | CA2CA1TP53MAPK1SLC1A3 | |
| SCHEMBL2808107 | 0.82 | CA2 (0.48) | CA2CA1TP53MAPK1SLC1A3 | |
| SCHEMBL4731976 | 0.81 | CA2 (0.49) | CA2CA1TP53EPHX1 | |
| SCHEMBL4732394 | 0.81 | CA2 (0.49) | CA2CA1TP53EPHX1 | |
| SCHEMBL4732707 | 0.81 | CA2 (0.49) | CA2CA1TP53EPHX1 | |
| SCHEMBL8525907 | 0.81 | CA2 (0.48) | CA2CA1TP53MAPK1SLC1A3 | |
| SCHEMBL15110520 | 0.78 | TP53 (0.47) | CA2CA1TP53SLC1A2SLC1A1 | |
| SCHEMBL14166660 | 0.77 | CA2 (0.49) | CA2CA1TP53EPHX1 | |
| SCHEMBL11310381 | 0.76 | TP53 (0.50) | CA2CA1TP53EPHX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CA2 743/4885CA1 3632/4885TP53 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.